ABSTRACT
INTRODUCTION
Gastrointestinal reflux disease is a common gastro intestinal disorder prevalent in western world. 1 Esophagitis occurs when the gastric acid move back to the esophagus. Regular backing of gastric acid causes the burning and erosion of esophagus. Reflux esophagitis causes severe heartburn and regurgitation. If not given proper treatment for healing of esopha gitis, it may result into chronic disorder. The other term to denote reflux esophagitis are gastroesophagal reflux disease (GERD), acid reflux disease etc. some of the common symptoms of reflux esophagitis includes heartburn, belching, upper abdominal pain, salivation,long term cough, vomiting etc. the failure of clearing the esophageal content is also responsible for reflux disease. 1, 2 H 2 receptor antagonists (cimetidine and ranitidine) are considered as most effective treatment for reflux disease since 1976 and these acts by reducing gastric acid secretion. 3, 4 The other comparable drug sucralfate has the same symptomatic relief as that of H 2 receptor antagonist. 5 But certain studies give the inconsistent result. So, we obtained a combined effect of efficacy of sucralfate in gastrointestinal reflux disease by performing metaanalysis on eligible studies. 6 In this 
METHODS

Identification and selection of studies
We searched the English literature for our studies published during January 1985 to October 2014. The databases searched for metaanalysis are PUBMED, MEDLINE, CINAHL, Cochrane central library and EMBASE. The key terms included in search strategy are reflux esophagitis, sucralfate, ranitidine, and cimetidine and these are applied to each database in consideration. Reflux esophagitis fetches 33,500 articles. We got 17,300 articles with by search of sucralfate. By combining search by keyword reflux esophagitis and sucralfate, it gives 1760 articles. We only searched for double blind and single blind randomized trials. We checked title, abstracts, con clusion for identification of required study.
After the searching in all mentioned databases, 1760 relevant articles are found, and these are further evaluated for inclusion and exclusion criteria. We also discussed with experts for any relevant detail " for our studies as mentioned in Figure 1 (the flowchart for metaanalyis used in the study).
Inclusion and exclusion criteria
Selection criteria are applied to our selected studies, to include study of interest in metaanalysis. The inclusion criteria for study is 1. The study should be either double blind or single blind randomized control trial 2. The intervention treatment is with sucralfate. 3. The study is compared with H 2 receptor antagonist (ranitidine or cimetidine). 4. Patient involved in study should have manifestation of esophagitis before entering into the study. 5. The healing of esophagitis occurs at four, eight and twelve weeks. Of 1760 identified trials, only eight trials met our inclusion criteria. 714 The one study from eight studies is excluded due to patient may not had esophagitis manifestation before entering into the study. 13 Finally, only seven trials included in our study ( Table 1 ). The study selected for meta analysis is all having same protocol for treatment. Information on healing of the symptoms of esophagitis is extracted from the trials. We have not applied any exclusion criteria. All the selected studies reviewed and obtained full texts for further evaluation in statistical analysis.
Extraction of data
From the selected studies, all data needed for the metaanalysis is obtained and feed to the statistical analysis. The data abstracted is 1. Name of studies 2. Number of patient (Number of men and women participants in study) 3. Year of publication 4. Location of studies 5. Study design 6. Age of patient 7. Alcohol consumption within patients 8. Smokers patients 9. Randomization ratio of patients. This data used in the metaanalysis. We contacted to authors if data is seem to be insufficient. The data from different studies is compared to each other.
Outcome measures
We have designed the endoscopically healing of ulcers as our primary outcome. From different study, healing of ulcers is occurred at interval four, eight and twelve weeks. The complete healing measured by endo scopically is taken into consideration. We combined this data as our outcome measure for metaanalysis. There are also secondary outcomes such as epigastric pain, nausea, headache but these are not considered in this study.
Identification of heterogeneity and publication bias
All the studies selected for metaanalysis are subjected to the estimation of heterogeneity and publication bias measurement. Funnel plot is used for the assessment of the publication bias within the studies. 15 Asymmetry of funnel plot leads to the publication bias. 15, 16 Heterogeneity measure ment is done by chisquare (χ 2 ) statistics and I 2 statistics. Pvalue less than 0.10 are indication of significant heterogeneity. Heterogeneity in study is estimated using Cochrane's Q and I 2 statistics. 17 I 2 statistics is derived from the Cochrane Q.
Where, df = degree of freedom I 2 greater than 50% represent significant heterogeneity in the study. If I 2 is equal to 0% then there is no heterogeneity among the studies.
RESULTS
The data extracted from study is subjected to metaanalysis. Dichotomous data calculated as odd ratio for the representation of effect size. The confidence is measured at 95% level. Pvalue is also measured for calcu lation statistical significant result. We have calculated weight for each study. Random effect model is applied to metaanalysis using DerSimonian and Laird method. ) value obtained is 5.17 (less than degree of freedom) which indicate there is no significant heterogeneity among studies. Pvalue less than 0.10 suggest the hetero geneity. So heterogeneity is absent in the Meta analysis of these studies. The funnel plot for six studies shows that there is no publication bias as depicted in Figure 2 . Studies are symmetrically distributed.The statistical calculations are performed using R packages. The packages used are "rmeta" and "meta" for forest plot as indicated in Figure 3 . And funnel plot as shown in Figure 2 .
DISCUSSION
Sucralfate and H 2 receptor antagonists are prescribed for the treatment of reflux esophagitis. The exaggerated movement of the gastric acid into the lower esophagus through lower sphincter causes the erosions to esophagus. 14 The reflux disease may lead to complex condition such as Barrett's epithelium and esophageal adenocarcinoma. 1 It is more common between 20 to 50 year patients and equally distributed in male and female. The drugs used for the treatment for common ulcers are ineffective in treating the esophageal erosions. The most common symptoms of reflux esophagitis are heartburn and regurgitation. 2 The available treatment for the treatment of reflux esophagitis are H 2 receptor antagonist (cimetidine, ranitidine etc.), proton pump inhibitors (lansoprazole, omeprazole etc.), prokinetics (cisapride, domperidone etc.), sucralfate are commonly used. 19 Certain study didn't mention the use of sucralfate in treatment of reflux disease 1 . In contrast to these study, we evaluated two treatments sucralfate and H 2 receptor antagonist for the treatment of reflux esophagitis. We compared the efficacy of both drugs using the technique metaanalysis. Metaanalysis is most effective approach for combining individual study. The metaanalysis performed for seven relevant studies containing more than 300 patient's shows that there is no statistical significant difference between the two treatments. We compared the seven different studies Elsborg and Jorgenesen (1991) Each study contains the different number of patients. We assess the effect of sucralfate on reflux disease in comparison to ranitidine and cimetidine. We compared the seven studies for metaanalysis involving more than 300 subjects. We considered the different baseline characteristic for each study. The numbers of male patients are more than the female patients. The combined pvalue obtained is 0.279 which is more than 0.05. In this research, we included the publication bias and the heterogeneity to boost our result. We assessed the heterogeneity and publication bias for the study of interest. We obtained the positive result for the publica tion bias and the heterogeneity. The chisquare statistics (χ 2 =5.17) and I 2 =0% shows the absence of heterogeneity in the trials. Funnel plots are used for the assessing of publication bias. Funnel plot shows the scat tered distribution of studies. The symmetry of funnel plot represents the absence of publication bias. We used odd ratio in calculating effect sizes rather than relative risk and hazard ratios. We also calculated the weight of each study. The metaanalysis is performed by using random effect model (DerSimonian and Laird method). Thus analysis of seven clinical trials suggests that we can use sucralfate as potential drug for treatment in place of ranitidine or cimetidine for the gastrointestinal reflux disease. The H 2 receptor antagonists are con sidered the effective treatment for treating gastrointestinal reflux disease still now. Conclusively from the metaanalysis performed on trials com paring treatment of sucralfate and ranitidine or cimetidine, we found that there is no statistical significant between the two treatments for treating reflux disease. From our findings, we can conclude that sucralfate is an effective alternative treatment for treating gastrointestinal reflux disease. The clinical effectiveness of sucralfate and that of H 2 receptor antagonists are comparable. So, we can focus our research on sucralfate for healing of the reflux esophagitis and gastrointestinal disorders. We can also relate sucralfate for other gastrointestinal disorders.
